Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -19.99% | -4.28% | 3.26% | 16.19% | 32.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.99% | -4.28% | 3.26% | 16.19% | 32.86% |
| Cost of Revenue | -16.35% | -3.86% | 3.12% | 11.05% | 29.10% |
| Gross Profit | -21.99% | -4.51% | 3.34% | 19.27% | 35.02% |
| SG&A Expenses | 6.28% | 10.51% | 27.20% | 83.10% | 19.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.26% | 4.13% | 16.29% | 44.16% | 24.07% |
| Operating Income | -137.46% | -78.02% | -66.97% | -70.43% | 164.42% |
| Income Before Tax | -124.44% | -71.39% | 28.75% | -40.89% | 155.59% |
| Income Tax Expenses | -- | -17.19% | 148.21% | -4.26% | -- |
| Earnings from Continuing Operations | -125.62% | -73.32% | 24.79% | -42.44% | 143.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.62% | -73.32% | 24.79% | -42.44% | 143.77% |
| EBIT | -137.46% | -78.02% | -66.97% | -70.43% | 164.42% |
| EBITDA | -129.27% | -70.69% | -62.41% | -68.47% | 145.62% |
| EPS Basic | -125.78% | -73.41% | 21.51% | -43.94% | 132.39% |
| Normalized Basic EPS | -124.73% | -71.53% | -63.57% | -68.26% | 144.16% |
| EPS Diluted | -129.60% | -75.00% | 16.67% | -41.55% | 150.00% |
| Normalized Diluted EPS | -126.88% | -70.11% | -63.36% | -68.41% | 129.14% |
| Average Basic Shares Outstanding | -0.79% | 0.09% | 2.71% | 2.63% | 5.01% |
| Average Diluted Shares Outstanding | -8.62% | -4.33% | 1.60% | 3.38% | 11.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |